Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) reported a strong start to 2023, with first-quarter revenue of $1.76 billion, marking a 5% year-over-year increase and 10% growth on a core basis. GAAP net income reached $352 million, an EPS of $1.19, up 28% from Q1 2022. Non-GAAP net income was $406 million, resulting in an EPS of $1.37, a 13% increase. The full-year revenue guidance has been raised to $7.03 billion to $7.10 billion, with anticipated growth of 2.7% to 3.7%.
Second-quarter revenue is projected between $1.655 billion and $1.680 billion, with non-GAAP EPS expected at $1.24 to $1.27.
Agilent Technologies Inc. (NYSE: A) has launched an on-deck thermal cycler (ODTC) accessory for its Bravo NGS automated liquid handling platform. This addition enhances the NGS sample preparation workflow by integrating thermal cycling into automated protocols. It significantly increases 'walk-away' time, allowing lab operators to focus on higher-level tasks. The ODTC is designed for use in various applications such as library preparation and target enrichment steps in NGS workflows. Agilent generated $6.85 billion in revenue in fiscal 2022 and continues to prioritize flexibility and productivity in lab settings.
Agilent Technologies (NYSE: A) announces the integration of its xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator, enhancing workflow automation in immuno-oncology and vaccine development. This combination allows for label-free, non-invasive analysis of cell proliferation, significantly increasing throughput and reducing sample sizes. The BioSpa 8 provides precise environmental controls, enabling researchers to automate assays with real-time data analysis. This innovative solution aims to expedite drug candidate screening amidst challenges in the evolving pharma landscape, reflecting Agilent's commitment to addressing critical health concerns.
Agilent Technologies Inc. (NYSE: A) has declared a quarterly dividend of 22.5 cents per share, set to be paid on April 26, 2023, to shareholders recorded by the close of business on April 4, 2023. The company, a leader in life sciences and diagnostics, reported $6.85 billion in revenue for fiscal 2022 and employs about 18,000 people globally. Future dividend amounts and timings will be subject to the board's approval. While the company aims to maintain its dividend program, various forward-looking uncertainties may impact its financial obligations.
Agilent Technologies (NYSE: A) will showcase automated laboratory workflow solutions at the SLAS2023 International Conference in San Diego from February 25 to March 1. The company has received the 'Lab of the Future' designation for its advanced integrated automation offerings aimed at enhancing lab efficiency and reproducibility in various applications including genomics and mass spectrometry. Agilent's automation solutions help reduce costs and human error while allowing scientists to focus on high-value tasks. Attendees can learn more about Agilent's innovations at booth #1811, where product tutorials and sessions will also be held.
Agilent Technologies Inc. (NYSE: A) recently broke ground on a $725 million expansion project in Frederick, Colorado, aimed at doubling its manufacturing capacity for therapeutic nucleic acids. This investment is expected to create over 160 life science jobs and enhance U.S. production of active pharmaceutical ingredients vital for treating various diseases, including cancer. The project will contribute to Colorado's biotechnology ecosystem and is anticipated to be completed by the end of 2026. CEO Mike McMullen highlighted the company’s commitment to innovative therapeutics that improve life quality.
Agilent Technologies (NYSE: A) has introduced the NovoExpress software, enhancing regulatory compliance for the NovoCyte flow cytometer systems. This update aids manufacturers in meeting FDA 21 CFR Part 11 and GxP guidelines, ensuring data integrity and authenticity. The software aims to improve productivity and efficiency in therapy development, manufacturing, and quality control. Agilent generated $6.85 billion in revenue in fiscal 2022 and continues its commitment to excellence in regulated markets.
Agilent Technologies Inc. (NYSE: A) is set to release its financial results for Q1 FY2023 on February 28, 2023, after market close. A live webcast will follow at 1:30 PM PT on the same day, accessible via the Events section of Agilent's investor relations website. In FY2022, Agilent generated $6.85 billion in revenue and employs approximately 18,000 people globally. Investors are encouraged to join the webcast for insights into the company’s performance and outlook.
Agilent Technologies (NYSE: A) has entered into a strategic agreement with Quest Diagnostics (NYSE: DGX) to facilitate access to the ctDx FIRST liquid biopsy next-generation sequencing test for advanced non-small cell lung cancer (NSCLC) patients in the U.S. This FDA-approved test will provide healthcare providers with a minimally invasive option to determine if patients could benefit from KRAZATI™ treatment. The collaboration aims to enhance the implementation of precision medicine in oncology, allowing healthcare providers to electronically order the test through Quest’s platform and utilize its extensive patient network.
Agilent Technologies (NYSE: A) has been recognized as one of the top 100 Most JUST companies, ranking 35 in the annual list by Just Capital and CNBC. This marks its fifth consecutive year in the ranking, with Agilent leading its sector in employee treatment, customer satisfaction, and environmental impact. Agilent's commitment to corporate responsibility is underlined by its recognition as a Great Place to Work in 20 countries and being listed among the best workplaces in health care by Fortune. The company's revenue reached $6.85 billion in fiscal 2022, employing 18,000 people globally.